All posts by BTS Research

GAO: Medicare’s Opioid Use Monitoring Lets At-Risk Patients Fall Through the Cracks

By | Drug Industry Daily | No Comments

The federal government’s guidance for monitoring opioid use among Medicare beneficiaries does not go far enough in identifying which beneficiaries are most at risk and the Centers for Medicare & Medicaid Services should collect data on exactly how many at-risk beneficiaries receive high doses, according to a new GAO report.
Source: Drug Industry Daily

FDA Highlights ConOps Progress

By | Drug GMP Report | No Comments

ORA and CDER officials provided an update last month on the agency’s Concept of Operations initiative in a panel discussion at the FDLI Enforcement Litigation and Compliance Conference in Washington D.C., detailing the next steps in implementing the concept.
Source: Drug GMP Report